On September 9, 2016, we signed an Exclusive Licensing and Supply Agreement with Reflexonic, LLC. Reflexonic sells and distributes urological medical devices, products, and related medical products. Reflexonic will assist in the development of urological products for the treatment of overactive bladder, interstitial cystitis and bladder pain syndrome by providing device therapeutic specifications, clinical evidence of effectiveness and regulatory market clearances.

ActiPatch will be the featured new product at Pharmacy Week October 16th to the 23rd by SuperPharm Limited, the leading Trinidad and Tobago pharmacy chain. SuperPharm is an integral part of the health care services and will provide consultation to patients on the therapeutic benefits and safety of drug free ActiPatch therapy.

We have submitted our “ActiPatch© Central Sensitization Therapy: A Chronic Back Pain Registry Study of Pain Relief & Analgesic Adverse Effects” survey for publication. The study reports that the majority of chronic back pain sufferers have less than adequate pain relief and that the majority of subjects were able to eliminate or reduce their analgesic drug use using ActiPatch.

The Company’s prior study Pain Management of 5,000+ users’ results A UK registry study of the effectiveness of a new over-the-counter chronic pain therapy, Pain Manag. 2015 Nov; 5(6): 413-23, was one of the Top 5 articles read out of all of the 28 Future Science Group Journals in 2106. Future Science Group is a progressive publisher focused on breakthrough medical biotechnological and scientific research.